This study is for adults with a type of pancreatic cancer called Metastatic Pancreatic Ductal Adenocarcinoma (PDAC). The study is looking at how safe and effective a drug called BMS-986504 is when used with two other cancer drugs, Nab-paclitaxel and Gemcitabine. The study will compare this treatment to a placebo (a fake treatment) with the same two cancer drugs. The study involves people who have a specific genetic change called MTAP deletion in their tumors.

Key Points:

• The study includes people with a confirmed diagnosis of PDAC that has spread to other parts of the body.
• Participants should not have had other cancer treatment for their metastatic cancer, except for one cycle of the study drugs.
• People with another active cancer within the last 2 years cannot join.

Note: This study helps understand if the new treatment is safe and works better than the standard treatment, and participants must meet specific health criteria to join.